Porton(SZ:300363) Xin Lang Cai Jing·2026-01-12 01:41Core Viewpoint - The stock of Boteng Co., Ltd. has shown a positive trend with a 2.61% increase on January 9, 2025, alongside significant trading activity and financial metrics indicating a stable position in the market [1]. Financing Summary - On January 9, 2025, Boteng Co. recorded a financing buy-in amount of 30.88 million yuan, with a net financing purchase of 6.22 million yuan after repayments [1]. - The total financing and securities balance for Boteng Co. reached 364 million yuan, accounting for 2.61% of its market capitalization, which is below the 30% percentile level over the past year, indicating a low financing balance [1]. - In terms of securities lending, the company had a securities lending balance of 26.11 thousand yuan, with a remaining quantity of 10,200 shares, also below the 20% percentile level over the past year [1]. Business Performance - For the period from January to September 2025, Boteng Co. achieved an operating revenue of 2.544 billion yuan, reflecting a year-on-year growth of 19.72% [2]. - The net profit attributable to the parent company was 79.92 million yuan, marking a significant year-on-year increase of 138.71% [2]. - The company's main business revenue composition includes 66.81% from late-stage clinical and commercialization, 25.76% from early-stage clinical, and 7.11% from emerging businesses [1]. Shareholder Information - As of December 19, 2025, the number of shareholders for Boteng Co. was 43,400, a decrease of 1.75% from the previous period, while the average circulating shares per person increased by 1.78% to 11,484 shares [2]. - The company has distributed a total of 1.193 billion yuan in dividends since its A-share listing, with 866 million yuan distributed over the past three years [3]. - Notable changes in institutional holdings include an increase in shares held by Hong Kong Central Clearing Limited to 23.98 million shares, while Tianhong Medical Innovation A reduced its holdings by 458,400 shares [3].